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probability that the outcome of interest exceeded the threshold. The posterior 
distribution had a 93.0% probability. When data from the ECST study formed the 
prior distribution, the posterior distribution had only a 57.5% probability of 
exceeding the threshold. This reflects a revised prior which included a lower 
(relative to ACAS) expectation of stroke in the AMM population as informed by 
ECST data. CONCLUSIONS: Bayesian analysis allows the incorporation of 
differing prior information, whether representing clinical opinion or clinical 
trials. This permits the observation of how differing priors affect the posterior 
distribution and, hence, interpretations of predicted clinical outcomes between 
treatments.  
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OBJECTIVES: The objective was to identify the optimal statistical method for 
regression analysis of the EQ-5D index. Specifically, we compared the 
performance of alternative regression methods in estimating incremental 
preference-based health related quality of life scores from the EQ-5D index. 
Importance of this work is high as preference-based scores derived from the EQ-
5D index are used to calculate quality-adjusted life years (QALYs), the most 
common measure of health outcomes used in cost-effectiveness analysis. Many 
health utility variables are censored from the top by construction, i.e. full health 
at unity. This is a utility measurement dilemma as 46% of US respondents report 
a perfect EQ-5D score. Also, EQ-5D is treated as a continuous variable; however 
due to its derivation algorithm there is a gap nearly equivalent to one standard 
deviation in the US preference-based scores of the EQ-5D index (no values 
between 0.8603 and 1). METHODS: Simulation analyses were implemented to 
compare the performance of OLS, median regression, Tobit, and robust 
extensions of Tobit models. First, pooled 2000-2003 Medical Expenditure Panel 
Survey data was randomly divided into independent derivation and validation 
sets to estimate the relationship between the EQ-5D index and SF-12 physical 
summary scores. Second, the performance of the same estimation methods was 
compared in a Monte Carlo simulation under ten non-normal distributions. 
RESULTS: Median regression outperformed all other methods in the first 
simulation analysis followed by the re-censored Tobit method. Median 
regression also resulted in the smallest mean squared prediction errors in the 
Monte Carlo simulations, followed by the Tobit method with logistic distribution. 
CONCLUSIONS: Median regression appears to be the most robust method to use 
in regression analysis of the EQ-5D index. If normality and homoscedasticity 
assumptions are not met, then logistic-Tobit regression can be used as a robust 
extension of the classical Tobit method.  
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OBJECTIVES: In 2000, Ontario initiated the world’s first universal influenza 
immunization program (UIIP). Our objective was to simulate the effect of this 
program on influenza attack rates using a new multi-strain dynamic influenza 
model. We compared our model results to a previous study of pre- and post-UIIP 
rates of influenza-associated events in Ontario. METHODS: Our model is age-
stratified, compartmental, and explicitly tracks two A strains (H1N1, H3N2) and 
two B lineages (Victoria, Yamagata). It also incorporates transmission rate 
seasonality, and accounts for non-homogeneous mixing among age groups via a 
contact matrix. U.S. age-stratified average yearly attack rates and the fraction of 
influenza A versus B cases were used as calibration targets. The resulting 
posterior sets of natural history parameters were run together with Ontario 
demographic and vaccine coverage data. RESULTS: Our simulations showed the 
following post-UIIP reduction in yearly attack rate: <5yrs: 48(31-62)%; 5-19yrs: 
49(33-64)%; 20-49yrs: 52(36-66)%; 50-64yrs: 58(42-71)%; 65-74yrs: 59(43-72)%; 75-
84yrs: 58(41-71)%; 85+yrs: 57(40-70)%. We compared our results to Kwong et al. 
(2008, PLoS Med 5(10): e211)’s analysis of post-UIIP reductions in influenza-
associated events, making the assumption that within each age group, event 
rates scale linearly with attack rates. Though qualitatively similar, overall their % 
reductions are at the upper end of our results. CONCLUSIONS: Our model results 
support the conclusion that Ontario’s Universal Influenza Immunization 
Program has brought about a significant reduction in the province’s incidence of 
influenza. Though the relative increase in vaccine uptake due to the UIIP was 
greatest below age 50, reductions in attack rate were greatest in ages 50 and 
over, indicating indirect benefit for the elderly. Reductions inferred by Kwong et 
al. (2008) are on the high side of our results, but this is consistent with their 
assertion that post-UIIP influenza seasons across Canada were intrinsically less 
severe during the study period. 
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OBJECTIVES: Key provisions of the 2006 Massachusetts health care reform and 
national legislation passed in 2010 were individual mandates to obtain health 
insurance. Increasing health insurance coverage is thought to lead to increased 
access to primary/preventive health care and improved patient outcomes. We 
examined the impact of Massachusetts health reform on preventable 
hospitalizations and cancers. METHODS: The Healthcare Cost and Utilization 
Project (HCUP), National Program of Cancer Registries (NPCR), and Surveillance, 
Epidemiology and End Results (SEER) databases were analyzed. Based on AHRQ’s 
Prevention Quality Indicators, preventable hospitalizations related to diabetes, 
hypertension, asthma, chronic obstructive pulmonary disease, and congestive 
heart failure (CHF) were analyzed. In addition, we examined incidence of 
preventable cancers (cervical and colon). Data from 2005 were compared to 
2009/2010 data; changes were examined both in Massachusetts and compared to 
national trends. RESULTS: The proportion of uninsured patients in 
Massachusetts decreased in 2010 compared to 2005 across all 5 categories of 
preventable hospitalizations. In Massachusetts, preventable discharges 
decreased only for diabetes and CHF. While the magnitude of decrease was 
greater in diabetes (-0.02% Massachusetts vs. -0.004% nationally), this trend was 
reversed in CHF (-0.17% vs. -0.31%). Results were similarly mixed across the 
remaining preventable hospital conditions. SEER data indicate that incidence of 
cervical and colon cancer decreased in both Massachusetts (-3.2/100,000 and  
-5.4/100,000 for cervical and colon cancer, respectively) and nationally  
(-1.2/100,000 and -3.6/100,000) from 2005-2009: the magnitude of decrease was 
larger in Massachusetts. Similar trends in colon cancer were found in NPCR data: 
incidence of colon cancer declined by 10.4/100,000 patients in Massachusetts 
compared with 6.9/100,000 nationally. CONCLUSIONS: Massachusetts health 
care reform has increased insurance coverage, though its impact on patient 
outcomes is less clear. As similar national legislation is implemented, research is 
needed to determine whether and how increased insurance coverage can be 
linked to improved patient outcomes.  
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OBJECTIVES: This study assesses the financial impact of Patient Protection and 
Affordable Care Act (PPACA) regulations on the pharmaceutical industry. 
METHODS: U.S. Public Law was searched from 2007 - 2012 to identify profit-
impacting regulatory changes on pharmaceutical and biotechnology 
manufacturers. Relevant results were then juxtaposed against aggregated and 
standardized Medicaid General Ledger accounts. A simple predictive model was 
built to examine the relationship. RESULTS: Public Law 111-148, Sec. 2501 
PRESCRIPTION DRUG REBATES indicated a change, effective as of March 23, 2010, 
increasing the minimum Medicaid Drug Rebate from 15.1% to 23.1% of the 
Average Manufacturer Price (AMP). The AMP is calculated as an aggregated 
average of all commercial sales transactions to and through retail community 
pharmacies. By modelling the top 100 manufacturers' average profit measures, it 
is estimated that the industry, on average, stood to lose a minimum of 8% in 
profitability in the Medicaid market segment. The Medicaid market segment 
comprises approximately 20% of all U.S. manufacturer sales, suggesting the 
PPACA could have a considerable impact on pharmaceutical profits overall. 
CONCLUSIONS: Basic statistical methods suggest that PPACA regulations may 
directly impact pharmaceutical company profits. Given the significant 
consolidation, acquisition, divestiture, and reorganization activities during this 
time period, it is possible that these regulations are indirectly reshaping the 
pharmaceutical industry landscape. Regression analyses should be conducted to 
analyze the link between the Medicaid rebate increases with manufacturer 
organizational change and subsequent business outcomes.  
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OBJECTIVES: The NHS is meeting efficiency savings through 4 areas: quality, 
innovation, productivity & prevention (QIPP). There is currently a considerable 
degree of uncertainty from the Department of Health (DH) as to whether the 
demand for health care is being managed in ways that inappropriately restricts 
patients’ access to care. Reducing demand and redesigning care pathways to 
treat patients in the most appropriate setting are key ways of generating savings. 
However transforming services within a prospective payment driven systems is 
fraught with difficulty. A review was undertaken of current Health Policies and 
Independent Government office findings e.g. National Audit Office (NAO) as to 
the likely reality of achieving efficiency saving via this route. METHODS: A 
survey of PCT clusters and NAO findings was undertaken to understand how 
these policy initiatives were being introduced and to understand the barriers to 
services transformation. RESULTS: In 2011-12 47% of PCT clusters reinvested less 
than a quarter of their cash releasing savings in transforming services. The 
perceived barriers to services transformation were perceived as; Lack of 
measures to invest first e.g. in community services; organizational barriers 
between health & social care including information sharing and differing 
financial priorities; lack of influence over acute providers; organizational barriers 
between acute and community services; some transformations would be better 
enforced at a regional or national level; staff across patient care pathways do not 
have the right skills; lack of evidence to convince stakeholders of the benefits of 
